Bolt Biotherapeutics Inc. (BOLT)
NASDAQ (CM) NASDAQ (CM) Primary 
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago.
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.28 per share a year ago.
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
BOLT FINAL DEADLINE: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders of Final Hours to Lead Class Action!
NEW YORK CITY, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
